Radioactive iodine therapy: multiple faces of the same polyhedron
暂无分享,去创建一个
[1] P. Rosário,et al. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies , 2021, Clinical endocrinology.
[2] M. Schlumberger,et al. Estimabl2: Is There a Need for Radioiodine Ablation in Low Risk Differentiated Thyroid Cancer (DTC) Patients?: Results From the French Randomized Phase III Prospective Trial on 776 Patients (NCT 01837745) , 2021, Journal of the Endocrine Society.
[3] Frederick D. Grant,et al. A JOINT STATEMENT FROM THE AMERICAN THYROID ASSOCIATION. , 2021, Thyroid : official journal of the American Thyroid Association.
[4] Kwangsoo Kim,et al. Long-Term Oncological Outcome Comparison between Intermediate- and High-Dose Radioactive Iodine Ablation in Patients with Differentiated Thyroid Carcinoma: A Propensity Score Matching Study , 2021, International journal of endocrinology.
[5] C. Kainickal,et al. Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (Review). , 2020, Molecular and clinical oncology.
[6] M. Schlumberger,et al. Current practice in patients with differentiated thyroid cancer , 2020, Nature Reviews Endocrinology.
[7] A. Maia,et al. Patterns of radioiodine use for differentiated thyroid carcinoma in Brazil: insights and a call for action from a 20-year database. , 2020, Archives of endocrinology and metabolism.
[8] N. Scalissi,et al. Intermediate-risk thyroid carcinoma: indicators of a poor prognosis. , 2020, Archives of endocrinology and metabolism.
[9] D. Goldstein,et al. Shared Decision-making in Head and Neck Surgery: A Review. , 2020, JAMA otolaryngology-- head & neck surgery.
[10] Zhihui Li,et al. The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer , 2020, PloS one.
[11] M. Papotti,et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] M. Luster,et al. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[13] Jinhua Zhao,et al. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma , 2019, Endocrine.
[14] S. Hawley,et al. Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Tuttle,et al. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. , 2019, The Journal of clinical endocrinology and metabolism.
[16] D. van Nostrand,et al. Conventional Radioiodine Therapy for Differentiated Thyroid Cancer. , 2019, Endocrinology and metabolism clinics of North America.
[17] W. Chung,et al. Pattern of urine iodine excretion with low iodine diet during preparation for radioactive iodine ablation in patients with thyroid cancer , 2018, Head & neck.
[18] C. Janovsky,et al. Thyroid cancer burden and economic impact on the Brazilian public health system , 2018, Archives of endocrinology and metabolism.
[19] M. Schlumberger,et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. , 2018, The lancet. Diabetes & endocrinology.
[20] C. Hong,et al. Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer , 2018, Nuclear Medicine and Molecular Imaging.
[21] R. Tuttle,et al. Controversial Issues in Thyroid Cancer Management , 2018, The Journal of Nuclear Medicine.
[22] A. Algeciras-Schimnich. Thyroglobulin measurement in the management of patients with differentiated thyroid cancer , 2018, Critical reviews in clinical laboratory sciences.
[23] C. Bylund,et al. Treatment decision making in early‐stage papillary thyroid cancer , 2018, Psycho-oncology.
[24] A. Ho,et al. Selective use of radioactive iodine (RAI) in thyroid cancer: No longer "one size fits all". , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[25] H. Zaidi,et al. Whole-Body SPECT/CT versus Planar Bone Scan with Targeted SPECT/CT for Metastatic Workup , 2017, BioMed research international.
[26] Nancy D Perrier,et al. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? , 2017, Thyroid : official journal of the American Thyroid Association.
[27] L. Moss,et al. SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective , 2017, The British journal of radiology.
[28] P. Ladenson,et al. Utility of I‐124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta‐analysis , 2017, Clinical endocrinology.
[29] S. Larson,et al. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry–Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer , 2017, The Journal of Nuclear Medicine.
[30] S. Jeong,et al. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer , 2017, Nuclear medicine communications.
[31] Kaliszewski,et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .
[32] A. Tischler,et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. , 2016, JAMA oncology.
[33] A. Bockisch,et al. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases , 2016, The Journal of Nuclear Medicine.
[34] Jee Soo Kim,et al. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma. , 2016, Endocrine-related cancer.
[35] Hon-Yi Shi,et al. Associations of Volume and Thyroidectomy Outcomes , 2016, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[36] R. Tuttle,et al. A Risk-adapted Approach to Follow-up in Differentiated Thyroid Cancer , 2016, Rambam Maimonides medical journal.
[37] J. Hennessey,et al. Low iodine diet in differentiated thyroid cancer: a review , 2016, Clinical endocrinology.
[38] S. Mandel,et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[39] T. Kasamatsu,et al. Assessment of the Effect of Two Distinct Restricted Iodine Diet Durations on Urinary Iodine Levels (Collected over 24 h or as a Single-Spot Urinary Sample) and Na+/I- Symporter Expression , 2015, European Thyroid Journal.
[40] K. Wong,et al. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. , 2015, The Journal of clinical endocrinology and metabolism.
[41] S. Filetti,et al. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. , 2015, The Journal of clinical endocrinology and metabolism.
[42] S. Roman,et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. , 2015, The Journal of clinical endocrinology and metabolism.
[43] E. Palmer,et al. Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib , 2014, Clinical Cancer Research.
[44] L. Duntas,et al. Thyroglobulin autoantibodies as surrogate biomarkers in the management of patients with differentiated thyroid carcinoma. , 2014, Current medicinal chemistry.
[45] C. Reiners,et al. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. , 2014, The Journal of clinical endocrinology and metabolism.
[46] Sarah J. Johnson,et al. Guidelines for the management of thyroid cancer , 2014, Clinical endocrinology.
[47] Michael Lassmann,et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[48] R. Tuttle,et al. Update on differentiated thyroid cancer staging. , 2014, Endocrinology and metabolism clinics of North America.
[49] Louise Davies,et al. Current thyroid cancer trends in the United States. , 2014, JAMA otolaryngology-- head & neck surgery.
[50] Mba Adam Hauch MD,et al. Total Thyroidectomy is Associated with Increased Risk of Complications for Low- and High-Volume Surgeons , 2014, Annals of Surgical Oncology.
[51] E. Soh,et al. Prognostic Significance of the Number of Metastatic Lymph Nodes to Stratify the Risk of Recurrence , 2014, World Journal of Surgery.
[52] David F. Schneider,et al. Remnant uptake as a postoperative oncologic quality indicator. , 2013, Thyroid : official journal of the American Thyroid Association.
[53] L. Duntas,et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. , 2013, Thyroid : official journal of the American Thyroid Association.
[54] R. Paschke,et al. 2013 European Thyroid Association Guidelines for Cervical Ultrasound Scan and Ultrasound-Guided Techniques in the Postoperative Management of Patients with Thyroid Cancer , 2013, European Thyroid Journal.
[55] R. Tuttle,et al. Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making. , 2013, Oral oncology.
[56] Yong Ding,et al. Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: Direct comparison and network meta-analyses , 2013, Journal of Endocrinological Investigation.
[57] Y. Yang,et al. Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinoma , 2013, Clinical and Translational Oncology.
[58] K. Frey,et al. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? , 2013, The Journal of clinical endocrinology and metabolism.
[59] S. Larson,et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.
[60] A. Gafni,et al. The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation. , 2013, Thyroid : official journal of the American Thyroid Association.
[61] Sebastiano Filetti,et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. , 2013, The Journal of clinical endocrinology and metabolism.
[62] J. Anthony Parker,et al. The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0* , 2012, The Journal of Nuclear Medicine.
[63] J. Golmard,et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. , 2012, European journal of endocrinology.
[64] Y. Ryu,et al. Knowledge, Self-Efficacy, and Perceived Barriers on the Low-Iodine Diet among Thyroid Cancer Patients Preparing for Radioactive Iodine Therapy , 2012, Clinical nutrition research.
[65] J. Franklyn,et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. , 2012, The New England journal of medicine.
[66] M. Schlumberger,et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. , 2012, The New England journal of medicine.
[67] P. Grigsby,et al. Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma , 2012, ISRN endocrinology.
[68] L. Staib,et al. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.
[69] N. Voirin,et al. Influence of experience on performance of individual surgeons in thyroid surgery: prospective cross sectional multicentre study , 2012, BMJ : British Medical Journal.
[70] J. Groopman,et al. Your Medical Mind: How to Decide What Is Right for You , 2011 .
[71] A. Iagaru,et al. Thyroid stunning: fact or fiction? , 2011, Seminars in nuclear medicine.
[72] M. Gapany. The Effectiveness of Radioactive Iodine for Treatment of Low-Risk Thyroid Cancer: A Systematic Analysis of the Peer-Reviewed Literature from 1966 to April 2008 , 2011 .
[73] U. Ekrikpo,et al. Increasing incidence of differentiated thyroid cancer in South East England: 1987–2006 , 2011, European Archives of Oto-Rhino-Laryngology.
[74] J. Shah,et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.
[75] John T. Chang,et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. , 2010, Thyroid : official journal of the American Thyroid Association.
[76] K. Koral,et al. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. , 2010, AJR. American journal of roentgenology.
[77] Markus Luster,et al. Dosimetry and thyroid cancer: the individual dosage of radioiodine. , 2010, Endocrine-related cancer.
[78] Min Jung Kim,et al. Diagnostic approach for evaluation of lymph node metastasis from thyroid cancer using ultrasound and fine-needle aspiration biopsy. , 2010, AJR. American journal of roentgenology.
[79] Glenn D. Flux,et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[80] Amy Y. Chen,et al. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005 , 2009, Cancer.
[81] D. van Nostrand,et al. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[82] T. Giordano,et al. Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine. , 2009, Thyroid : official journal of the American Thyroid Association.
[83] A. Gafni,et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. , 2008, Endocrinology and metabolism clinics of North America.
[84] A. Gafni,et al. Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. , 2007, Thyroid : official journal of the American Thyroid Association.
[85] David D. Smith,et al. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope , 2007, Journal of surgical oncology.
[86] R. Wahl,et al. Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging–Based Internal Dosimetry , 2007, Journal of Nuclear Medicine.
[87] J. Jonklaas,et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. , 2006, Thyroid : official journal of the American Thyroid Association.
[88] W. Wiersinga,et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.
[89] E. Baudin,et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.
[90] Á. Barroso,et al. Ultrasonographic Differentiation Between Metastatic and Benign Lymph Nodes in Patients With Papillary Thyroid Carcinoma , 2005, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[91] R. Tsang,et al. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years , 2005, Clinical endocrinology.
[92] J. Sandbank,et al. Differentiated Thyroid Carcinoma in Children and Young Adults: Evaluation of Response to Treatment , 2005, Clinical nuclear medicine.
[93] E. Vignali,et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens , 2003, Annals of Internal Medicine.
[94] D. Weightman,et al. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma , 2003, Cancer.
[95] S. Gulec,et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[96] M. Graif,et al. Cystic appearance of cervical lymph nodes is characteristic of metastatic papillary thyroid carcinoma , 2003, Journal of clinical ultrasound : JCU.
[97] R. Kloos,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .
[98] N. Powe,et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. , 1998, Annals of surgery.
[99] V S Hertzberg,et al. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[100] M. Sonenberg,et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.
[101] C. Gilbert,et al. Radioiodine in thyroid cancer. , 1952, British medical bulletin.
[102] S. M. Seidlin,et al. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. , 1946, Journal of the American Medical Association.